Tags: Drug.

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued as no new information on the drug has surfaced since December 2008.

Mubritinib_2.svg
ATC prefix
none
CAS number
366017-09-6
FDA UNII code
V734AZP9BR
IUPAC name
1-(4-4-[(2-(E)-2-[4-(trifluoromethyl)phenyl]ethenyl-13-oxazol-4-yl)methoxy]phenylbutyl)-1H-123-triazole
PubChem
6444692

Loading...

This page contains content from the copyrighted Wikipedia article "Mubritinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.